Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Beyond Air, Inc. is a medical device and biopharmaceutical company focused on developing and commercializing nitric oxide (NO)–based therapies for respiratory and infectious diseases. The company operates primarily in the medical technology and pulmonary care industries, with a core emphasis on hospital-based therapies. Its flagship product is the LungFit® platform, a cylinder-free system designed to generate nitric oxide on demand from ambient air, addressing limitations associated with traditional high-pressure gas cylinder delivery systems.
The company generates and expects to generate revenue primarily through the sale, rental, and servicing of LungFit systems and related consumables, along with potential future revenues from therapeutic indications under development. Beyond Air serves hospitals, neonatal intensive care units, and critical care settings, targeting clinicians treating conditions such as hypoxic respiratory failure. Founded in 2014, the company evolved from a development-stage technology firm into a publicly traded company following its initial public offering in 2020, with its strategy centered on expanding approved indications and global adoption of its proprietary NO generation technology.
Business Operations
Beyond Air operates as a single-reportable-segment company, with its core operations centered on the development, manufacturing, and commercialization of its LungFit® nitric oxide delivery systems. Revenue is derived from device placements, recurring disposable components, and service-related agreements, with a business model that emphasizes recurring usage within hospital settings. The company maintains control over its proprietary plasma-based NO generation technology, which differentiates it from traditional compressed-gas competitors.
Operations include research and development activities to support regulatory approvals for additional indications, post-market studies, and next-generation devices. While commercial operations are primarily focused on the United States, Beyond Air also pursues international distribution through third-party partners. The company does not report material joint ventures; however, it has established distribution and collaboration agreements to support commercialization outside its direct sales footprint.
Strategic Position & Investments
Beyond Air’s strategic direction centers on expanding the clinical utility of nitric oxide therapy through new indications, broader hospital adoption, and international market entry. Growth initiatives include pursuing regulatory approvals for additional respiratory and infectious disease indications and increasing utilization of LungFit systems in existing customer accounts. The company continues to invest heavily in research and development to validate NO’s antimicrobial and antiviral properties.
The company has not completed large-scale acquisitions and instead focuses on organic growth driven by its proprietary technology platform. Beyond Air maintains a portfolio of patents covering NO generation and delivery, which it views as a core strategic asset. Emerging areas of interest include the potential use of inhaled nitric oxide in treating drug-resistant infections and inflammatory lung conditions, although some applications remain in clinical or investigational stages.
Geographic Footprint
Beyond Air is headquartered in the United States, with its principal executive offices located in New York State. The company’s primary commercial market is North America, where it conducts direct sales and customer support activities targeting hospitals and neonatal intensive care units.
Internationally, Beyond Air has established a presence through distribution partners in Europe, Asia-Pacific, and parts of the Middle East, reflecting its strategy to expand LungFit adoption outside the U.S. While international revenues currently represent a smaller portion of overall activity, the company views global markets as an important long-term growth opportunity tied to regulatory approvals and healthcare infrastructure development.
Leadership & Governance
Beyond Air is led by an executive team with experience in medical devices, pharmaceuticals, and commercial-stage healthcare companies. The leadership emphasizes innovation, regulatory discipline, and the clinical validation of nitric oxide therapies as core elements of its strategic vision.
- Steve Lisi – Chief Executive Officer
- Amir Avniel – Founder and Chief Technology Officer
- Michael Myers – Chief Financial Officer
- Elizabeth Andonian – Chief Commercial Officer
- Robert Goodman – Chief Medical Officer
The company operates under a board-governed structure consistent with U.S. public company standards, with oversight focused on capital allocation, regulatory compliance, and long-term shareholder value creation.